HCID 90037368, Verbindung → (2S,3S)-3-Amino-2,8-dimethyl-2,3-dihydrobenzo[b][1,4]oxazepin-4 (5H)-one trifluoro acetate
Reaktionsgleichung
[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].N[C@H]1COC2C=C(C)C=CC=2NC1=O.[CH3:22][C@@H:23]1[O:29][C:28]2[CH:30]=[C:31]([CH3:34])[CH:32]=[CH:33][C:27]=2[NH:26][C:25](=[O:35])[C@H:24]1[NH:36]C(=O)OC(C)(C)C>>[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[NH2:36][C@H:24]1[C@H:23]([CH3:22])[O:29][C:28]2[CH:30]=[C:31]([CH3:34])[CH:32]=[CH:33][C:27]=2[NH:26][C:25]1=[O:35]Komponenten
3
Reaktionsbedingungen
- Temperatur
- 0 °C
Versuchsvorschrift
In a similar manner to that described for the preparation of (S)-3-amino-8-methyl-2,3-dihydrobenzo[b][1,4]oxazepin-4(5H)-one trifluoroacetate except the reaction mixture was stirred at 0° C. for 30 min. and at RT for 20 min., tert-butyl (2S,3S)-2,8-dimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-ylcarbamate was converted to the title compound (175 mg, 112%) which was used without purification.